Yi Ren

Also affiliated with First People's Hospital of Chongqing, Southeast University

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “FDA Approval Summary: Dabrafenib in Combination with Trametinib for BRAFV600E Mutation–Positive Low-Grade Glioma”.

FDA Approval Summary: Dabrafenib in Combination with Trametinib for BRAFV600E Mutation–Positive Low-Grade Glioma

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-1503

N/A

1.8DataRank · unranked

71 citations

Jeannette Nashed, Diana Bradford, Yi Ren, Sachia G. Khasar, Claudia P. Miller +15 more

Evaluating immune response and metabolic related biomarkers pre-allogenic hematopoietic stem cell transplant in acute myeloid leukemia

PLoS ONE(2022)10.1371/journal.pone.0268963

N/A

0DataRank · unranked

3 citations

Felicia Cao, Jing Lyu, Yi Ren, Andrew B. Nixon, Jichun Xie +10 more

FDA Approval Summary: Repotrectinib for Locally Advanced or Metastatic ROS1-Positive Non–Small Cell Lung Cancer

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-0949

N/A

0DataRank · unranked

14 citations

Diana Bradford, Yi Ren, Stephanie Aungst, Claudia P. Miller, Lili Pan +19 more